We are monitoring the impact of COVID-19 on Antibody Drug Conjugates Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 5792
Share on
Share on

Global Antibody Drug Conjugates Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By pipeline, Technology, End User & Region - Industry Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 5792
Pages: 175

Antibody Drug Conjugates Market Size (2021 to 2026):

The global antibody-drug conjugates market size is forecasted to grow USD 44.45 Billion by 2026 from USD 14.72 Billion in 2021, growing at a CAGR of 24.74% between 2021 to 2026.

Antibody-drug conjugates are very effective biopharmaceutical drugs that are used to treat certain diseases. Antibody-drug conjugates are a type of cancer treatment that is safer and more effective than many other cancer treatments. Antibody-drug conjugates, unlike chemotherapy, are designed to target and destroy just cancer cells. Antibody-drug conjugates are a type of chemical molecule that combines antibodies with a cytotoxic medication that is physiologically active. Antibody-drug conjugates are composed of three components: a particular antibody for binding, a cytotoxic agent to kill cancer cells, and a chemical linker to connect the cytotoxic agent to the antibody. These drug conjugates are thought to be the medicinal agents of the future. The potency of a cytotoxic agent embedded in an antibody-drug conjugate is 100–1000 times more than the potency of the cytotoxic agent acting alone. Formulating an antibody-drug conjugate cancer has been difficult for a long time.

Nonetheless, the pharmaceutical industry's modernization aided the market in overcoming hurdles such as identifying a target, generating a high-affinity antibody, internalization capabilities, linker creation, and drug stability and optimization. According to the National Cancer Institute, "by 2024, the number of people living beyond the cancer diagnosis is predicted to reach over 19 million." During the research period, the ADC market is likely to be driven by increased demand for cost-effective and high-quality cancer therapy.

MARKET DRIVERS:

The global antibody-drug conjugates market growth is majorly driven by the factors such as an increase in the prevalence of cancer and a growing geriatric population across the globe.

The market growth is further propelled by ongoing technological advancements in the healthcare sector. The World Health Organization (WHO) predicts that by 2050, the number of persons aged 65 and more would have increased to 16% of the overall population, up from 7% in 2000. In developing nations, aging has become a significant risk factor for various illnesses, including cancer and others. As a result, the market's growth is likely to be fuelled by the expanding elderly population throughout the forecast period. Also, significant innovative progressions are assisting the market growth.  However, the growing use of Antibody Drug Conjugates in various segments of end-users across emerging nations is a factor driving market expansion.

Furthermore, preclinical research, increased antibody therapy research, increased research on advanced drug discoveries, and increased research on cancer disorders all impact market growth. A biomacromolecule was created by combining monoclonal antibodies with chemical payloads, and it is today one of the most potent weapons in the complete immunotherapy arsenal. Moreover, rising chronic diseases such as cancer and the growing obese population are most likely to augment the market growth. In addition, increasing collaboration between research institutions, biopharmaceutical firms, and biotechnology firms fuel the market. They are likely to increase the market of antibody-drug conjugates throughout the forecast period. The market for cancer antibody-drug conjugates and the boom that has resulted from a high number of new medications in the clinical pipeline has been effective in attracting global attention. Increasing investments by pharmaceutical and biotechnology companies are encouraging market growth. The market's major players are concentrating on various growth tactics, such as acquiring regulatory clearance for new products to increase their product range. For example, the U.S. Food and Drug Administration (FDA) approved Policy, an antibody-drug conjugate, by Roche Holding AG, a Swiss healthcare business, in June 2019.

MARKET RESTRAINTS:

Stringent government regulations and reimbursement policies are impeding market growth. High costs associated with the procedures and the lack of funds are further expected to hamper the growth rate of the global antibody drug conjugates market.

COVID-19 impact on the global antibody drug conjugates market:

The Global pandemic COVID-19 is a highly contagious disease spread across 210 countries and had affected more than 2 million and led to many people dying. As a result of the steps taken by various governments to limit transmission, a massive economic catastrophe ensued. The outbreak of COVID-19 has impacted the market, resulting in a market decline in the first half of 2020. The reduction is mostly due to the COVID-19 outbreak, which has resulted in tight containment measures such as social separation, remote working, and the shutdown of companies and other businesses. The entire supply chain has been interrupted, which has had a detrimental impact on the antibody drug conjugates market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Pipeline, Technology, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Seattle Genetics, Genentech, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, and Synthon Biopharmaceuticals.

 

This market research report on the global antibody drug conjugates market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2026.

Antibody Drug Conjugates Market - By Pipeline:

  • Phase
  • Mode of action
    • Igg1 antibodies
    • HER2 antibodies
  • Technology
  • Linker

Antibody Drug Conjugates Market - By Technology:

  • Seattle Genetics
  • Immunogen
  • Immunomedics

Antibody Drug Conjugates Market - By End User:

  • Research institutes
  • Hospitals
  • Clinics

Antibody Drug Conjugates Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American market is expected to lead the global antibody drug conjugates market during the forecast period. The North American antibody drug conjugates market was worth 3.6 billion in 2020. The rise in awareness among patients of early diagnosis is driving the North American market. The increase in usage of antibody-drug conjugates (ADC) and the rise in the prevalence of cancer are further accelerating the North American market. The United States is forecasted to dominate the North American Antibody Drug Conjugates Market during the forecast period due to the presence of high cancer patients, increased investments by the market participants in the pipeline analysis, and technological advancements. The Canadian market is expected to grow at a significant CAGR due to increased government funding in the research and large pharmaceutical companies.

The European antibody-drug conjugate market is predicted to be the second-largest regional market globally and estimated to value USD 7.56 billion in 2025. Y-O-Y growth in the number of cancer & bone marrow surgeries happening in Europe, rise in awareness programs by the government, and the presence of significant market players are majorly promoting the European market. In Europe, the German market is predicted to dominate, followed by France and U.K. The presence of favorable reimbursement policies and the rise in government and private to develop advanced technology in these regions propels the European antibody-drug conjugate market.

The Asia-Pacific region is the fastest-growing region in the global market due to the rise in prevalence of cancer, and expanding health care infrastructure is driving the market. The rising awareness among consumers and growing government initiatives are propelling the Asia Pacific Antibody Drug Conjugates Market.

Latin America, and Middle East & Africa are expected to have lucrative growth opportunities in the coming years.

KEY MARKET PARTICIPANTS:

Some of the promising companies operating in the global antibody drug conjugate market profiled in the report are Seattle Genetics, Genentech, Takeda Pharmaceuticals, Hoffmann-La Roche, Bayer Healthcare, Agensys, Inc., Immunogen, Novartis, Oxford Biotherapeutics, Synthon Biopharmaceuticals.

KEY MARKET DEVELOPMENTS:

  • On March 31, 2020, Oxford Biotherapeutics, a leading clinical-stage oncology industry that produces immune-oncology and antibody-drug conjugate-based therapies, has made a public statement that they have chosen formal IND enabling studies.
  • On March 22, 2019, Takeda Pharmaceutical company and LegoChem Biosciences announced that both the companies have agreed to become one for the development of antibody-drug conjugate for cancer therapies. 
  1. Introduction         
    1. Antibody Drug Conjugates Market Definition                    
    2. Study Deliverables                  
    3. Base Currency, Base Year and Forecast Periods  
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases                      
      1. Secondary Research           
      2. Primary Research 
      3. Econometric Modelling      
    3. Expert Validation
    4. Analysis of Design Study Timeline
  3. Overview 
    1. Executive Summary                
    2. Key Inferences 
    3. Epidemiology      
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)            
    1. Antibody Drug Conjugates Market Drivers  
    2. Antibody Drug Conjugates Market Restraints                    
    3. Key Challenges 
    4. Current Opportunities in the Antibody Drug Conjugates Market
  5. Antibody Drug Conjugates Market Segmentation
    1. Pipeline
      1. Introduction           
      2. Phase
      3. Mode of Action
        1. IgG1 Antibodies
        2. HER2 Antibodies
      4. Y-o-Y Growth Analysis, By Pipeline           
      5. Market Attractiveness Analysis, By Pipeline         
      6. Market Share Analysis, By Pipeline
    2. By Technology
      1. Seattle Genetics
      2. Immunogen
      3. Immunomedics
    3. End-User            
      1. Research institutes            
      2. Hospitals 
      3. Clinics       
      4. Others     
      5. Y-o-Y Growth Analysis, By End User             
      6. Market Attractiveness Analysis, By End User           
      7. Market Share Analysis, By End User
  6. Geographical Analysis                      
    1. Introduction 
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
        1. By Geographical Area
        2. By Pipeline
        3. By Technology
        4. By End-User
      4. Market Attractiveness Analysis
        1. By Geographical Area
        2. By Pipeline
        3. By Technology
        4. By End-User
      5. Market Share Analysis
        1. By Geographical Area
        2. By Pipeline
        3. By Technology
        4. By End-User
    2. North America  
      1. Introduction           
      2. United States         
      3. Canada
    3. Europe
      1. Introduction
      2. U.K
      3. Spain
      4. Germany 
      5. Italy
      6. France       
    4. Asia-Pacific
      1. Introduction
      2. China
      3. India
      4. Japan
      5. Australia
      6. South Korea           
    5. Latin America
      1. Introduction
      2. Brazil
      3. Argentina
      4. Mexico
      5. Rest of Latin America          
    6. Middle East & Africa
      1. Introduction
      2. Middle-East
      3. Africa         
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social         
      4. Technological         
      5. Legal          
      6. Environmental       
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers        
      2. Bargaining Power of Consumers
      3. The threat of New Entrants
      4. The threat of Substitute Products and Services              
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Seattle Genetics      
      1. Overview
      2. Product Analysis
      3. Financial analysis
      4. Recent Developments
      5. SWOT analysis
    2. Analyst View
      1. Genentech
      2. Takeda Pharmaceuticals 
      3. Hoffmann-La Roche 
      4. Bayer Healthcare
      5. Agensys, Inc
      6. Immunogen
      7. Novartis
      8. Oxford Biotherapeutic
      9. Synthon Biopharmaceuticals   
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities                 

Appendix

  1. List of Tables
  2. List of Figures      
  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms Technology along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Antibody Drug Conjugates  Market By Region, From 2021 to 2026 ( USD Billion )
  2. Global Antibody Drug Conjugates  Market By Pipeline Analysis, From 2021 to 2026 ( USD Billion )
  3. Global Phase Market By Region, From 2021 to 2026 ( USD Billion )
  4. Global Mode of action Market By Region, From 2021 to 2026 ( USD Billion )
  5. Global Technology Market By Region, From 2021 to 2026 ( USD Billion )
  6. Global Linker Market By Region, From 2021 to 2026 ( USD Billion )
  7. Global Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  8. Global Research institutes Market By Region, From 2021 to 2026 ( USD Billion )
  9. Global Hospitals Market By Region, From 2021 to 2026 ( USD Billion )
  10. Global Clinics Market By Region, From 2021 to 2026 ( USD Billion )
  11. Global Others Market By Region, From 2021 to 2026 ( USD Billion )
  12. North America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  13. North America Phase Market By Region, From 2021 to 2026 ( USD Billion )
  14. North America Mode of action Market By Region, From 2021 to 2026 ( USD Billion )
  15. North America Technology Market By Region, From 2021 to 2026 ( USD Billion )
  16. North America Linker Market By Region, From 2021 to 2026 ( USD Billion )
  17. North America Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  18. North America Research institutes Market By Region, From 2021 to 2026 ( USD Billion )
  19. North America Hospitals                    Market By Region, From 2021 to 2026 ( USD Billion )
  20. North America Clinics Market By Region, From 2021 to 2026 ( USD Billion )
  21. North America Others Market By Region, From 2021 to 2026 ( USD Billion )
  22. United States Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  23. United States Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  24. Canada Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  25. Canada Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  26. Europe Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  27. Europe Phase Market By Region, From 2021 to 2026 ( USD Billion )
  28. Europe Mode of action Market By Region, From 2021 to 2026 ( USD Billion )
  29. Europe Technology Market By Region, From 2021 to 2026 ( USD Billion )
  30. Europe Linker Market By Region, From 2021 to 2026 ( USD Billion )
  31. Europe Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  32. Europe Research institutes Market By Region, From 2021 to 2026 ( USD Billion )
  33. Europe Hospitals Market By Region, From 2021 to 2026 ( USD Billion )
  34. Europe Clinics Market By Region, From 2021 to 2026 ( USD Billion )
  35. Europe Others Market By Region, From 2021 to 2026 ( USD Billion )
  36. U.K. Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  37. U.K. Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  38. Germany Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  39. Germany Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  40. France Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  41. France Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  42. Italy Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  43. Italy Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  44. Spain Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  45. Spain Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  46. Asia Pacific Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  47. Asia Pacific Phase Market By Region, From 2021 to 2026 ( USD Billion )
  48. Asia Pacific Mode of action Market By Region, From 2021 to 2026 ( USD Billion )
  49. Asia Pacific Technology Market By Region, From 2021 to 2026 ( USD Billion )
  50. Asia Pacific Linker Market By Region, From 2021 to 2026 ( USD Billion )
  51. Asia Pacific Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  52. Asia Pacific Research institutes Market By Region, From 2021 to 2026 ( USD Billion )
  53. Asia Pacific Hospitals Market By Region, From 2021 to 2026 ( USD Billion )
  54. Asia Pacific Clinics Market By Region, From 2021 to 2026 ( USD Billion )
  55. Asia Pacific Others Market By Region, From 2021 to 2026 ( USD Billion )
  56. Japan Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  57. Japan Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  58. China Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  59. China Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  60. India Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  61. India Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  62. Australia Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  63. Australia Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  64. South Korea Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  65. South Korea Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  66. Latin America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  67. Latin America Phase Market By Region, From 2021 to 2026 ( USD Billion )
  68. Latin America Mode of action Market By Region, From 2021 to 2026 ( USD Billion )
  69. Latin America Technology Market By Region, From 2021 to 2026 ( USD Billion )
  70. Latin America Linker Market By Region, From 2021 to 2026 ( USD Billion )
  71. Latin America Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  72. Latin America Research institutes Market By Region, From 2021 to 2026 ( USD Billion )
  73. Latin America Hospitals Market By Region, From 2021 to 2026 ( USD Billion )
  74. Latin America Clinics Market By Region, From 2021 to 2026 ( USD Billion )
  75. Latin America Others Market By Region, From 2021 to 2026 ( USD Billion )
  76. Brazil Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  77. Brazil Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  78. Argentina Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  79. Argentina Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  80. Mexico Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  81. Mexico Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  82. Rest of Latin America Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  83. Rest of Latin America Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  84. Middle East and Africa Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  85. Middle East and Africa Phase Market By Region, From 2021 to 2026 ( USD Billion )
  86. Middle East and Africa Mode of action Market By Region, From 2021 to 2026 ( USD Billion )
  87. Middle East and Africa Technology Market By Region, From 2021 to 2026 ( USD Billion )
  88. Middle East and Africa Linker Market By Region, From 2021 to 2026 ( USD Billion )
  89. Middle East and Africa Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  90. Middle East and Africa Research institutes Market By Region, From 2021 to 2026 ( USD Billion )
  91. Middle East and Africa Hospitals Market By Region, From 2021 to 2026 ( USD Billion )
  92. Middle East and Africa Clinics Market By Region, From 2021 to 2026 ( USD Billion )
  93. Middle East and Africa Others Market By Region, From 2021 to 2026 ( USD Billion )
  94. Middle East Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  95. Middle East Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )
  96. Africa Antibody Drug Conjugates  Market By Pipeline Analysis , From 2021 to 2026 ( USD Billion )
  97. Africa Antibody Drug Conjugates  Market By End-user , From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample